Hepatocellular Carcinoma Recurrence After Liver Transplantation.
Hepatocellular Carcinoma Recurrence After Liver Transplantation.
Oncology (Williston Park). 2020 Mar 19;34(3):
Authors: Gabutti A, Bhoori S, Cascella T, Bongini M
Abstract
Key Points • Recurrent HCC after OLT management is challenging and notoriously difficult. • High oncologic-risk patient identification and close follow-up are essential. • Recurrences diagnosed within the first 2 years after OLT can be classified as early-onset and are associated with poor prognosis. • Surgical resection should be the first curative attempt when it is technically feasible. • TACE in patients who have undergone OLT appears to be effective and safe. • Sorafenib can be used as systemic therapy in cases with multi-organ recurrence; newer therapies are emerging. • The benefit of immunosuppression with an mTOR inhibitor has not been established. • In the posttransplant setting, a combination treatment approach is warranted.
PMID: 32212134 [PubMed - in process]
Source: Oncology (Williston Park, N.Y.) - Category: Cancer & Oncology Authors: Gabutti A, Bhoori S, Cascella T, Bongini M Tags: Oncology (Williston Park) Source Type: research
More News: Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Liver | Liver Cancer | Liver Transplant | Transplants | Urology & Nephrology